

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 9th July 2019 12:30 pm
Cobalt conference centre, Level 2
Northumbria Healthcare NHS Foundation Trust
Northumbria House
7-8 Silver Fox Way
Cobalt Business Park
North Shields
NE27 0QJ

AGENDA

1.	Apologies for absence Neil Watson Paul Fieldhouse	
2.	Declarations of interest	
3.	Election of FSC chair	
4.	Terms of reference <ul style="list-style-type: none"> • Role of APC in ICS/ICP/Place 	Enc.1.
5.	Appeals against previous decision <ul style="list-style-type: none"> • None 	
6.	Minutes from the meeting 2/04/19 Decision summary from 2/04/19	Enc.2. Enc.3.
7.	Matters arising not on the agenda	
8.	APC Action log <ul style="list-style-type: none"> • June 2019 update 	Enc.4.
9.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 16/5/19 • Draft decision summary from meeting held on 16/5/19 <ul style="list-style-type: none"> ○ 2016 Dymista application ○ 2016 Dymista appeal notification ○ 2019 application ○ Allergic Rhinitis Pathway - 2019 ○ Dymista supporting document - 2019 	Enc.5. Enc.6a. Enc.6b Enc.6c Enc.6d Enc.6e Enc.6f

10.	<p>Items which should not routinely be prescribed in primary care:</p> <ul style="list-style-type: none"> • Guidance for CCGs Version 2, June 2019 https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-prescribed-in-pc-ccg-guidance-v2.pdf <ul style="list-style-type: none"> ○ Aliskiren ○ Amiodarone ○ Bath and shower preparations for dry and pruritic skin conditions ○ Drondarone ○ Minocycline for acne ○ Needles for pre-filled and reusable insulin pens ○ Silk garments 	Enc.7.
11.	<p>Report from the Medicines Guidelines and Use Group</p> <ul style="list-style-type: none"> • Draft minutes from meeting held on 3/6/19 • Guidelines/documents for approval <ul style="list-style-type: none"> ○ Lithium shared care ○ Nebulised gentamicin guidance ○ Guidance on lanreotide and octreotide • Guidance to retire: <ul style="list-style-type: none"> ○ Diagnosis and Management of Patients with Peripheral Arterial Disease (PAD) ○ Primary management of drug prescribing in non-malignant pain ○ Modafinil information leaflet ○ Mexiletine information leaflet ○ Methotrexate prescribing advice • Guidance agreed to remove from website pending update: <ul style="list-style-type: none"> ○ Erectile dysfunction ○ Headache guidelines 	Enc.8. Enc.9. Enc.10. Enc.11.
12.	<p>Opiate/pain management sub-group</p> <ul style="list-style-type: none"> • Minutes for Opiate/pain management meeting held on 24.4.19 • Data 	Enc.12. Enc.13a &13b
13.	<p>RMOCs</p> <ul style="list-style-type: none"> • RMOC Deprescribing Guideline: Topic Selection survey • RMOC newsletter 3, 2019 https://www.sps.nhs.uk/articles/regional-medicines-optimisation-committee-newsletter-issue-3-2019/ • RMOC newsletter 4, 2019 https://www.sps.nhs.uk/articles/regional-medicines-optimisation-committee-newsletter-issue-4-2019/ • RMOC Guidance: Principles guiding the decision making about the route of supply of medicines to outpatients https://www.sps.nhs.uk/articles/principles-guiding-the-decision-making-about-the-route-of-supply-of-medicines-to-outpatients-rmoc-guidance/ • RMOC newsletter 5, 2019 https://www.sps.nhs.uk/wp-content/uploads/2019/06/RMOC-newsletter-issue-5-2019-v2.pdf • RMOC Position Statement on the Rarely Used and Urgent Medicines List https://www.sps.nhs.uk/articles/rarely-used-and-urgent-medicines-list/ 	Email 18/4/19 Email 8/5/19 Enc.14. Email 15/5/19 Enc.15. Enc.16. Enc.17. Enc.18.

14.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/</p> <p>The updated NTAG Position Statement on Flash Glucose Monitoring was published on 16/4/19. http://ntag.nhs.uk/html/endocrine.php. This was approved by APC chairs action on 16.4.19.</p> <p>The following further recommendations were finalised on 4/6/19:</p> <ul style="list-style-type: none"> • Flash Glucose Monitoring Minor update. • Alfapump® device for the treatment of ascites due to Liver Cirrhosis – no change to recommendation but clinical evidence section updated. <p>The formulary will reflect these recommendations. NTAG annual report covering June 2018 – June 2019</p>	<p>Enc.19.</p> <p>Enc.20.</p> <p>Enc.21.</p>
15.	<p>NICE Technology Appraisals published since last meeting - formulary to be amended to reflect the following:</p> <ul style="list-style-type: none"> • TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma • TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis • TA575 Tildrakizumab for treating moderate to severe plaque psoriasis • TA576 – terminated appraisal Bosutinib for untreated chronic myeloid leukaemia • TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma • TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation • TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy • TA580 - negative appraisal Enzalutamide for hormone-relapsed non-metastatic prostate cancer • TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma • TA582 Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) • TA583 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes • TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer • TA585 Ocrelizumab for treating primary progressive multiple sclerosis • TA586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib • TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma 	
16.	<p>NHS England</p> <ul style="list-style-type: none"> • Spec Comm Drugs Briefing - Spring 2019 • Specialised Services circulars <ul style="list-style-type: none"> ○ SSC1991 - EAMS – Atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression $\geq 1\%$ 	<p>Enc.22.</p> <p>Enc.23.</p>

- SSC1992 - NICE TA FAD: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma after at least 1 systemic therapy (ID1190)
- SSC1993 - NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma
- SSC1994 - NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
- SSC1995 - NICE TA 565: Benralizumab for treating severe eosinophilic asthma
- SSC1996 - NICE TA FAD: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
- SSC1999 - Axicabtagene Ciloleucel and Tisagenlecleucel CAR T therapies
- SSC2000 - NICE TA FAD: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
- SSC2001 - Mexiletine (NaMuscla®) for the treatment of myotonia in patients with non-dystrophic myotonic disorders
- SSC2002 - NICE TA FAD: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
- SSC2003 - NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma
- SSC2011 - NICE TA FAD: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
- SSC2017 - NICE TA FAD: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
- SSC2018 - NICE TA FAD: Lenalidomide for previously untreated multiple myeloma
- SSC2019 - Trientine for Wilson Disease (all ages) NHS England Reference: 170094P
- SSC2025 - Pembrolizumab Flat Dosing for adults in currently funded indications for Hodgkin's Lymphoma, Malignant Melanoma, Non Small Cell Lung Cancer and Urothelial Cancers
- SSC2026 - NICE TA 561: Venetoclax with rituximab for previously treated relapsed or refractory chronic lymphocytic leukaemia
- SSC2027 - NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
- SSC2029 - EAMS – Atezolizumab in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)
- SSC2032 - NICE TA FAD: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
- SSC2033 - NICE TA 571 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
- SSC2035 - NHS England Policy: Updated implementation guidance for Cinacalcet for complex primary hyperparathyroidism in adults - Reference 16034/P
- SSC2037 - EAMS: polatuzumab vedotin in combination with bendamustine and rituximab

17.	Chairman's action <ul style="list-style-type: none">• Endorsement of NTAG position statement on Freestyle Libre	Email 16/4/19
18.	Any other business	
19.	Date, time and venue of next meetings: Cobalt conference centre, Level 2 Northumbria Healthcare NHS Foundation Trust Northumbria House 7-8 Silver Fox Way Cobalt Business Park North Shields NE27 0QJ Tuesday 8th October 2019 12:30 pm	